Desmoid: The Role of Local Therapy In an Era of Systemic Options
Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment mod...
Gespeichert in:
Veröffentlicht in: | Current treatment options in oncology 2013-09, Vol.14 (3), p.465-473 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 473 |
---|---|
container_issue | 3 |
container_start_page | 465 |
container_title | Current treatment options in oncology |
container_volume | 14 |
creator | Walczak, Brian E. Rose, Peter S. |
description | Opinion statement
Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection. |
doi_str_mv | 10.1007/s11864-013-0235-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1431296255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3065753071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</originalsourceid><addsrcrecordid>eNp1kM9LwzAUx4Mobk7_AC9S8OKlmh9N0nhS5tTBYKDzHJI01Y62qUl72H9vS6eI4OmF9z7v-8IHgHMErxGE_CYglLIkhojEEBMa8wMwRZQkMcOcHw5vzGPMsZiAkxC2EGKaQHEMJphwBgUSU3D3YEPliuw22nzY6MWVNnJ5tHJGlUPHq2YXLetI1dHCq2H0ugutrQoTrZu2cHU4BUe5KoM929cZeHtcbObP8Wr9tJzfr2JDOG5jSommggmKUgM15JngjHCaYEWYhdpoIRjUlGYi5TwhBFmjMpTrXHGtRSrIDFyNuY13n50NrayKYGxZqtq6LkiUEIQFw_2hGbj8g25d5-v-dwMFOUx7ez2FRsp4F4K3uWx8USm_kwjKQa8c9cperxz0St7vXOyTO13Z7Gfj22cP4BEI_ah-t_7X6X9TvwCC-oFh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430708100</pqid></control><display><type>article</type><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Walczak, Brian E. ; Rose, Peter S.</creator><creatorcontrib>Walczak, Brian E. ; Rose, Peter S.</creatorcontrib><description>Opinion statement
Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-013-0235-7</identifier><identifier>PMID: 23760919</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>beta Catenin - genetics ; Combined Modality Therapy ; Drug Therapy ; Fibromatosis, Aggressive - diagnosis ; Fibromatosis, Aggressive - drug therapy ; Fibromatosis, Aggressive - genetics ; Fibromatosis, Aggressive - pathology ; Fibromatosis, Aggressive - surgery ; Humans ; Maf Transcription Factors - genetics ; Maf Transcription Factors - metabolism ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Oncology ; Sarcoma (SH Okuno ; Section Editor</subject><ispartof>Current treatment options in oncology, 2013-09, Vol.14 (3), p.465-473</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</citedby><cites>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-013-0235-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-013-0235-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23760919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walczak, Brian E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement
Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</description><subject>beta Catenin - genetics</subject><subject>Combined Modality Therapy</subject><subject>Drug Therapy</subject><subject>Fibromatosis, Aggressive - diagnosis</subject><subject>Fibromatosis, Aggressive - drug therapy</subject><subject>Fibromatosis, Aggressive - genetics</subject><subject>Fibromatosis, Aggressive - pathology</subject><subject>Fibromatosis, Aggressive - surgery</subject><subject>Humans</subject><subject>Maf Transcription Factors - genetics</subject><subject>Maf Transcription Factors - metabolism</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Oncology</subject><subject>Sarcoma (SH Okuno</subject><subject>Section Editor</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM9LwzAUx4Mobk7_AC9S8OKlmh9N0nhS5tTBYKDzHJI01Y62qUl72H9vS6eI4OmF9z7v-8IHgHMErxGE_CYglLIkhojEEBMa8wMwRZQkMcOcHw5vzGPMsZiAkxC2EGKaQHEMJphwBgUSU3D3YEPliuw22nzY6MWVNnJ5tHJGlUPHq2YXLetI1dHCq2H0ugutrQoTrZu2cHU4BUe5KoM929cZeHtcbObP8Wr9tJzfr2JDOG5jSommggmKUgM15JngjHCaYEWYhdpoIRjUlGYi5TwhBFmjMpTrXHGtRSrIDFyNuY13n50NrayKYGxZqtq6LkiUEIQFw_2hGbj8g25d5-v-dwMFOUx7ez2FRsp4F4K3uWx8USm_kwjKQa8c9cperxz0St7vXOyTO13Z7Gfj22cP4BEI_ah-t_7X6X9TvwCC-oFh</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Walczak, Brian E.</creator><creator>Rose, Peter S.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><author>Walczak, Brian E. ; Rose, Peter S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>beta Catenin - genetics</topic><topic>Combined Modality Therapy</topic><topic>Drug Therapy</topic><topic>Fibromatosis, Aggressive - diagnosis</topic><topic>Fibromatosis, Aggressive - drug therapy</topic><topic>Fibromatosis, Aggressive - genetics</topic><topic>Fibromatosis, Aggressive - pathology</topic><topic>Fibromatosis, Aggressive - surgery</topic><topic>Humans</topic><topic>Maf Transcription Factors - genetics</topic><topic>Maf Transcription Factors - metabolism</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Oncology</topic><topic>Sarcoma (SH Okuno</topic><topic>Section Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walczak, Brian E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walczak, Brian E.</au><au>Rose, Peter S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Desmoid: The Role of Local Therapy In an Era of Systemic Options</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>14</volume><issue>3</issue><spage>465</spage><epage>473</epage><pages>465-473</pages><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement
Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23760919</pmid><doi>10.1007/s11864-013-0235-7</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1527-2729 |
ispartof | Current treatment options in oncology, 2013-09, Vol.14 (3), p.465-473 |
issn | 1527-2729 1534-6277 1534-5277 |
language | eng |
recordid | cdi_proquest_miscellaneous_1431296255 |
source | MEDLINE; SpringerLink Journals |
subjects | beta Catenin - genetics Combined Modality Therapy Drug Therapy Fibromatosis, Aggressive - diagnosis Fibromatosis, Aggressive - drug therapy Fibromatosis, Aggressive - genetics Fibromatosis, Aggressive - pathology Fibromatosis, Aggressive - surgery Humans Maf Transcription Factors - genetics Maf Transcription Factors - metabolism Medicine Medicine & Public Health Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery Oncology Sarcoma (SH Okuno Section Editor |
title | Desmoid: The Role of Local Therapy In an Era of Systemic Options |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A02%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Desmoid:%20The%20Role%20of%20Local%20Therapy%20In%20an%20Era%20of%20Systemic%20Options&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Walczak,%20Brian%20E.&rft.date=2013-09-01&rft.volume=14&rft.issue=3&rft.spage=465&rft.epage=473&rft.pages=465-473&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-013-0235-7&rft_dat=%3Cproquest_cross%3E3065753071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1430708100&rft_id=info:pmid/23760919&rfr_iscdi=true |